acegame 888
Giants face challenge in hosting Ravens, trying to end 8-game skid
5 Stocks To Watch in December—And What To Watch ForInside abandoned mortuary with grisly tools and medical files left untouched
Photos: Remembering Jimmy Carter, the 39th US president
If you're looking for top stocks, there's no need to reinvent the wheel. The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors. Every three months, the regulator has everyone with more than $100 million under management share their trading details with the public on a Form 13F filing. One billionaire investor whom investors of all sizes follow closely is Philippe Laffont of Coatue Management. Known for investing in a combination of tech and healthcare stocks, Laffont grew his fund to $26.9 billion at the end of September. Laffont and Coatue made a lot of money with Nvidia in the first half of 2024. At the end of June, Wall Street's favorite artificial intelligence ( AI ) stock was the fund's fourth-largest holding at a value of roughly $1.2 billion. His love for Nvidia found a limit. During the third quarter, Coatue sold 3.6 million shares of the high-flying AI stock, which was enough to reduce its stake by 26%. Nvidia has fallen out of favor at Coatue and been replaced by a pair of two drugmakers leading the anti-obesity niche. During the third quarter, Laffont increased his firm's stake in Novo Nordisk ( NVO -0.32% ) more than ninefold to $39 million. Coatue already had a large Eli Lilly ( LLY -1.38% ) stake that it raised by 20% to $220 million. 1. Novo Nordisk The drugs that Novo Nordisk and Eli Lilly market for the treatment of obesity and diabetes are flying off pharmacy shelves and have further to climb. A report from Morgan Stanley suggests the market for anti-obesity drugs could rise from $6 billion in 2023 to $105 billion in 2030. Novo's lead drug is semaglutide, a glucagon-line peptide-1 (GLP-1) agonist that the Food and Drug Administration (FDA) approved as Ozempic and Rybelsus to treat diabetes and later as Wegovy to treat obesity. In the first nine months of 2024, total semaglutide sales grew about 41% year over year to $19.8 billion. In a clinical trial leading to its approval as a weight management drug, Wegovy reduced patients' weight by 12.4% compared to a placebo. Novo Nordisk isn't stopping at Wegovy. It's developing a next-generation weight management treatment made from semaglutide and an amylin analog called CagriSema (cagrilintide). Treatment with CagriSema lowered patients' weight by a placebo-adjusted 20.4% on average after 68 weeks of treatment. 2. Eli Lilly Eli Lilly is another large pharmaceutical company with a blockbuster GLP-1 drug. Tirzepatide first earned FDA approval to treat diabetes in 2022 under the brand name Mounjaro. The FDA approved the same drug to treat obesity in 2023 under the brand name Zepbound. While semaglutide acts on GLP-1 alone, tirzepatide is a dual GLP-1 and GIP agonist. The dual action has improved its efficacy and sales trajectory. In trials leading to Zepbound's approval, it reduced patients' weight by a placebo-adjusted 17.8% on average after 72 weeks. Novo Nordisk still has a leading share of the market for GLP-1 drugs, but tirzepatide is gaining fast. Despite just two short years on the market, total tirzepatide sales during the first nine months of 2024 rose above $11 billion. CagriSema could disrupt tirzepatide's upward trajectory, but there's a good chance Eli Lilly will overtake Novo Nordisk as the leading seller of GLP-1 drugs. Although CagriSema's pivotal trial results were impressive, they pale in comparison to retatrutide, a triplet therapy Eli Lilly is testing. Retatrutide is a GLP-1/GIP agonist that also acts on glucagon receptors. In 2023, a phase 2 trial showed it lowered patients' weight by a placebo-adjusted 22.1% after 48 weeks. Time to buy? The GLP-1 drug market will be stuck in a game of tug-of-war between Eli Lilly and Novo Nordisk for the next several years. Tirzepatide will likely overtake semaglutide in another year or two, but it could fall to CagriSema. Novo Nordisk's next-generation anti-obesity candidate already finished a phase 3 trial and could earn FDA approval in 2025. Retatrutide began a phase 3 study in May of 2023 that should wrap up in January of 2026. If all goes as expected, CagriSema could be the top obesity treatment for about a year before the FDA looks at an application from Lilly for retatrutide. While we can reasonably look forward to rapid sales growth from their still-experimental GLP-1 candidates, the stock market is already pricing in a lot of success. Expectations are so high for Eli Lilly that it's probably best to avoid the stock for now. It's been trading for about 60 times forward-looking earnings estimates. At this steep valuation, any sign of trouble for tirzepatide or retatrutide could lead to heavy losses. Shares of Novo Nordisk recently tanked because CagriSema results don't appear competitive against retatrutide. At its recently beaten-down price, the pharmaceutical giant is trading for 27.9 times forward-looking earnings expectations. That's a steep price to pay for a drugmaker, but soaring demand for its GLP-1 drugs could allow it to grow into its valuation and provide market-beating gains to patient investors.Baltimore (8-5) at New York Giants (2-11) Sunday, 1 p.m. EST, CBS BetMGM NFL Odds: Ravens by 16. Against the spread: Ravens 6-6-1; Giants 4-9. Series record: Ravens lead 5-3. Last meeting: Giants beat the Ravens 24-20 on Oct. 16, 2022, in East Rutherford, N.J. Last week: Ravens had a bye; Giants lost to Saints 14-11. Ravens: overall (1), rush (2), pass (5), scoring (3) Ravens defense: overall (22), rush (1), pass (32), scoring (23) Giants offense: overall (26), rush (15), pass (28), scoring (32) Giants defense: overall (16), rush (29), pass (6), scoring (T14) Turnover differential: Raven plus-2; Giants minus-8. Ravens player to watch K Justin Tucker is having the worst season of his outstanding career, and the potentially windy conditions in East Rutherford could post another challenge for him. Baltimore would love to see some signs that he's rounding into form as the playoffs draw closer. Giants player to watch QB Tommy DeVito. He is probably going to get his second start of the season with Drew Lock in a walking boot. The New Jersey product didn't do much in a 30-7 loss to Tampa Bay in his first start. He was 21 of 31 for 189 yards and no touchdowns. Key matchup Playing without Pro Bowler Dexter Lawrence and fellow defensive tackle Rakeem Nunez-Roches, the young line held its own against Alvin Kamara and the Saints last week, limiting the team to 92 yards rushing on 33 carries. Slowing down the league's No. 1 offense and No. 2 running game led by Lamar Jackson and Derrick Henry will be a lot tougher. Key injuries Ravens: WR Rashod Bateman (knee) practiced this week, and Balticmore is generally pretty healthy following its open date. NT Michael Pierce (calf) and LB Kyle Van Noy (hamstring/neck) practiced as well. Giants: CB Deonte Banks (ribs), ILB Bobby Okereke (back), Nunez-Roches (shoulder-neck), T Chris Hubbard (knee), CB Dru Phillips (shoulder), LT Jermaine Eluemunor (quad) all missed last week and could be out again. ... QB Drew Lock (heel), LG Jon Runyan Jr. (ankle) and CB Tre Hawkins (back) were hurt in the game. Hawkins and S Tyler Nubin (ankle) were placed on injured reserve. Runyan is week to week. Lock is unlikely. T Evan Neal (hip-ankle), T Josh Ezeudu (knee), S Dane Belton (knee), WR Malik Nabers (hip), DL Jordon Riley (knee) are on the injury report. Series notes The Giants have won the past three games, including the most recent one in Brian Daboll's first season as coach. The Ravens won the biggest game, beating New York 34-7 in the Super Bowl in Tampa, Fla., on Jan. 28, 2001. Stats and stuff The Ravens are coming off a bye week. ... Baltimore averages an NFL-leading 422.5 yards of offense. ... Jackson has had an NFL-best eight games of two or more touchdown passes and no interceptions. He's had no picks in 6 of 7 road games this season. ... WR Zay Flowers leads the team with 74 catches. ... Mark Andrews is tied for second among NFL tight ends with seven touchdown receptions. ... LB Roquan Smith aims for his fourth game in a row with at least 11 tackles. He is tied for fifth in the league with 121 tackles. ... LB Kyle Van Noy recovered a fumble for touchdown in his only game against the Giants. ... LB Odafe Oweh has had a sack in his past two road games. ... Nabers leads the Giants with 80 catches, 819 yards and three touchdown receptions. Fellow rookie RB Tyrone Tracy leads the team with 664 yards rushing and five TDs. ... WR Wan’Dale Robinson is second behind Nabers with 67 catches. The Giants are the only team with two players with at least 67 receptions. ... The Giants have an NFL-low eight touchdown receptions. ... Nubin led all rookies with 97 tackles before going on IR. ... Hawkins had an interception last week, the Giants' first since the season opener. ... OLB Brian Burns had a sack, two tackles for loss and a forced fumble against the Saints. .... ILB Micah McFadden had a team-high 11 tackles, including five for losses last week. He is the fifth player in the past five seasons with five TFLs in one game. ... OLB Kayvon Thibodeaux had sack and two TFLs last week. Fantasy tip Ravens RB Derrick Henry. He rushed for 170 yards and two touchdowns in only road game against the Giants. He is tied for the NFL lead with 15 overall TDs, 13 rushing. The 30-year-old is second in the league with 1,407 yards rushing and 1,532 yards from scrimmage. ___ AP NFL: https://apnews.com/hub/nfl The Associated PressGal Gadot reveals she had blood clot in her brain, emergency surgery
FMC Corporation announces election of Anthony DiSilvestro to Board of DirectorsWalker's 20 help IU Indianapolis knock off Trinity Christian 106-49Trump offers support for dockworkers union by saying ports shouldn't install more automated systems
- Previous: s888 games
- Next: king game888
